読み込み中
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
前日終値
$21.00
+$0.16 · +0.77%
時間外
$21.10
+$0.10 · +0.48%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
日中レンジ
現在 $21.00
52週レンジ
現在 $21.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
47
適正価値
センチメント
49
まちまち
リスク
52
やや高いリスク
モメンタム
69
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
日中レンジ
現在 $21.00
52週レンジ
現在 $21.00
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 27.23億 USD | 26.96億 USD | 28.43億 USD | 28.37億 USD | 30.58億 USD |
| 売上原価 | 22.98億 USD | 21.62億 USD | 22.52億 USD | 21.13億 USD | 24.53億 USD |
| 粗利益 | 4.26億 USD | 5.34億 USD | 5.91億 USD | 7.24億 USD | 6.04億 USD |
| 販売・一般管理 | 4.56億 USD | 5.61億 USD | 4.48億 USD | 4.16億 USD | 3.03億 USD |
| 営業費用 | 4.56億 USD | 6.96億 USD | 5.59億 USD | 5.37億 USD | 4.9億 USD |
| 支払利息 | 9140万 USD | 1.24億 USD | 6980万 USD | 20万 USD | 20万 USD |
| 減価償却費と償却費 | 7800万 USD | 8690万 USD | 9800万 USD | 9360万 USD | 1.66億 USD |
| 営業利益 | −3060万 USD | −1.62億 USD | 3200万 USD | 1.87億 USD | 1.14億 USD |
| 純利益 | −9.86億 USD | −3.29億 USD | −2520万 USD | 1.86億 USD | 9800万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$20.50
下落余地（2.38%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI5503.14万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM5248.8万0.07%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF2014.51万0.02%954億 USD0.05%$233.52-0.63%
Vanguard Morningstar Small-Cap ETFVB1997.3万0.01%1853億 USD0.03%$288.16-0.46%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1820.03万0.11%157.12億 USD0.03%$53.42-0.06%
Invesco S&P SmallCap Momentum ETFXSMO1744.46万0.61%28.69億 USD0.35%$81.31-0.54%
Schwab Fundamental U.S. Small Company Index ETFFNDA1650.56万0.19%87.82億 USD0.25%$35.60-0.06%
iShares Biotechnology ETFIBB1523.41万0.14%108.2億 USD0.44%$204.26-1.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMInvesco S&P SmallCap Momentum ETFXSMOSchwab Fundamental U.S. Small Company Index ETFFNDAiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
